Newsletter - April 8, 2021
Are FDA’s In-Person Meetings Coming Back in the Fall?
One of the casualties of the pandemic last year was the in-person meetings with FDA reviewers. For obvious reasons, FDA converted all its meetings since March 2020 to the virtual or phone call format as an alternate to in-person meetings on the FDA campus. Now, as the pandemic slowly winds down in the US...Read More
How Many Covid Vaccines Do We Need? Fate of Tier 2 Vaccines Seems Grim.
There are still about 50 vaccines for Covid-19 in Phase 1 clinical trials, and 77 in non-clinical development. Of the 86 vaccines in clinical trials, 23 have reached Phase 3 clinical trials the world over, 13 of which have been approved or authorized in at least one country. The Covid vaccine market is already quite crowded. Read More
Are FDA’s In-Person Meetings Coming Back in the Fall?
One of the casualties of the pandemic last year was the in-person meetings with FDA reviewers. For obvious reasons, FDA converted all its meetings since March 2020 to the virtual or phone call format as an alternate to in-person meetings on the FDA campus. Now, as the pandemic slowly winds down in the US...Read More
How Many Covid Vaccines Do We Need? Fate of Tier 2 Vaccines Seems Grim.
There are still about 50 vaccines for Covid-19 in Phase 1 clinical trials, and 77 in non-clinical development. Of the 86 vaccines in clinical trials, 23 have reached Phase 3 clinical trials the world over, 13 of which have been approved or authorized in at least one country. The Covid vaccine market is already quite crowded. Read More
